Windtree Therapeutics, Inc.

3:00 PM - 3:15 PM (PDT), Wednesday, June 15, 2022
Windtree Therapeutics is advancing multiple late-stage interventions for acute cardiovascular and pulmonary syndromes to support patients in their moments of crisis. Windtree's goal is to develop unique therapies that significantly improve upon the treatment of severe, acute conditions, such as heart failure, early cardiogenic shock, lung injury associated with COVID-19 and neonatal respiratory distress--addressing some of the most underserved and costly acute conditions.
Ticker:
WINT
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
1992
Main Therapeutic Focus:
Lead Product in Development:
Istaroxime
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Speaker
photo
Chief Executive Officer & President
Windtree Therapeutics, Inc.